Therapeutics: Estrogen-related receptor α (ERR-α; ESRRA; NR3B1); phosphoinositide 3-kinase (PI3K); mammalian target of rapamycin (mTOR; FRAP; RAFT1)

Cancer

INDICATION: Breast cancer

Cell and mouse studies suggest combining inhibitors of ERR-α with inhibitors of PI3K or PI3K/mTOR could help treat triple-negative

Read the full 215 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE